Synonym: (S)-3-(3,4-Dihydroxyphenyl)-2-hydrazino-2-methylpropanoic acid; S-(−)-α-Hydrazino-3,4-dihydroxy-2-methylbenzenepropanoic acid
CAS Number: 28860-95-9
Empirical Formula (Hill Notation): C10H14N2O4
Molecular Weight: 226.23
EC Number: 249-271-9
MDL Number: MFCD00069231
Linear Formula: C10H14N2O4
Product Type: Chemical
This picture is provided solely for illustration purposes. Optical properties of the actual product may deviate. Relevant product information is printed on labeled products and other accompanying or available information material. This image depicts SKU: C1335-100MG
| assay |
≥98% (TLC) |
| form |
powder |
| InChI |
1S/C10H14N2O4/c1-10(12-11,9(15)16)5-6-2-3-7(13)8(14)4-6/h2-4,12-14H,5,11H2,1H3,(H,15,16)/t10-/m0/s1 |
| InChI key |
TZFNLOMSOLWIDK-JTQLQIEISA-N |
| Quality Level |
200  |
| SMILES string |
CC(Cc1ccc(O)c(O)c1)(NN)C(O)=O |
| solubility |
methanol and 1 drop HCl: 4.90-5.10 mg/mL, clear, colorless to faintly yellow |
| storage temp. |
−20°C |
| Biochem/physiol Actions: |
Peripheral inhibitor of L-aromatic amino acid decarboxylase. |
| Biochem/physiol Actions: |
Peripheral inhibitor of L-aromatic amino acid decarboxylase. When co-administered with L-DOPA, it prevents extra-CNS conversion to dopamine, thereby increasing CNS concentrations of effective compounds. Selectively cytotoxic to human pulmonary carcinoid and small cell lung carcinoma cells by increasing H2O2 in these cell lines, which are sensitive to reactive oxygen species. |
| General description: |
Carbidopa is used for treating restless legs (RL) syndrome and periodic leg movements in sleep (PLMS). Carbidopa along with levodopa is used to treat Parkinson′s disease. |
| Packaging: |
100 mg in glass bottle |
| Packaging: |
25 mg in poly bottle |
| RIDADR |
NONH for all modes of transport |
| WGK Germany |
WGK 3 |
| Flash Point(F) |
Not applicable |
| Flash Point(C) |
Not applicable |
| Purity |
≥98% (TLC) |
| Storage Temp. |
−20°C |
| UNSPSC |
12352202 |